IL1A and TNF receptor 1-associated periodic fever syndrome: Anti-IL-1 agents were indicated as beneficial in the majority of patients with TRAPS (LoE = 2B; SoR = B) also as maintenance treatment (LoE = 2B-3; SoR = C).